Kinaset Therapeutics
Kinaset Therapeutics Raises $103M Series B | Inhalable JAK Inhibitor for Asthma
Kinaset Therapeutics Closes $103M for Asthma Drug
Kinaset Therapeutics, developing an inhalable pan-JAK inhibitor for severe asthma, has raised $103 million in Series B funding.
The round was co-led by RA Capital Management and Forge Life Science Partners with participation from EQT Life Sciences, Vivo Capital, and Schroders Capital.
Key Highlights
- Inhalable pan-JAK inhibitor (frevecitinib)
- Targets severe asthma patients
- Minimal systemic side effects
Company Overview
Kinaset Therapeutics is developing frevecitinib, an inhalable pan-JAK inhibitor designed to target lung inflammation in severe asthma patients while minimizing systemic effects.
Company Info
Investors (4)
Share
Related Reports
Tebra Raises $250M Growth Financing | Healthcare Practice Management Platform
Healthcare practice management platform Tebra secures $250 million in growth financing led by Hildred Capital for AI-driven automation.
Harmattan AI Raises $200M Series B | Defense Tech Unicorn at $1.4B Valuation
French defense tech company Harmattan AI secures $200 million Series B led by Dassault Aviation, reaching unicorn status.
AirNexis Therapeutics Raises $200M Series A | Novel COPD Treatment
Biotech AirNexis Therapeutics emerges from stealth with $200 million Series A for dual PDE3/4 inhibitor COPD therapy.
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free